Table 3 Patient and tumour characteristics of pT1a-pT1b tumours vs other stage I-II tumours in the NEMESI study
From: Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study
Pathological stage I-II (pT1a, pT1b excluded) | pT1a, pT1b | |
|---|---|---|
N. of patients | 1492 | 402 |
Distribution by age | ||
18–34 | 23 (1.5%) | 7 (1.7%) |
35–49 | 384 (25.7%) | 85 (21.1%) |
50–69 | 754 (50.5%) | 230 (57.2%) |
≥ 70 | 331 (22.2%) | 80 (19.9%) |
Menopausal status | ||
Pre- | 465 (31.2%) | 101 (25.1%) |
Post- | 1,014 (68.0%) | 293 (72.8%) |
Unknown | 13 (0.9%) | 8 (2.0%) |
Node sentinel biopsy | ||
Yes | 903 (60.5%) | 319 (79.3%) |
No | 589 (39.5%) | 83 (20.7%) |
Axillary nodal dissection | ||
Yes | 941 (63.1%) | 137 (34.1%) |
No | 551 (36.9%) | 265 (65.9%) |
Grading | ||
G1 | 120 (8.0%) | 101 (25.1%) |
G2 | 741 (48.7%) | 221 (55.0%) |
G3 | 589 (39.5%) | 72 (17.9%) |
Unknown | 42 (2.8%) | 8 (2.0%) |
Proliferation index (Ki-67/MB1) | ||
0–18% | 707 (47.4%) | 283 (70.6%) |
19–29% | 279 (18.7%) | 52 (12.9%) |
≥ 30% | 461 (30.9%) | 54 (13.4%) |
Unknown | 45 (3.0%) | 13 (3.2%) |
ER status | ||
ER positive (≥ 10%) | 1,215 (81.4%) | 351 (87.3%) |
ER negative (0–9%) | 276 (18.5%) | 51(12.7%) |
Unknown | 1 (0.1%) | 0 (0.0%) |
PgR status | ||
PgR positive (≥ 10%) | 1,038 (69.6%) | 300 (74.6%) |
PgR negative (0–9%) | 449 (30.1%) | 101(25.4%) |
Unknown | 5 (0.3%) | 0 (0.0%) |
Hormonal status* | ||
ER and/or PgR positive | 1,228 (82.3%) | 354 (88.1%) |
ER and PgR negative | 263 (17.6%) | 48(11.9%) |
Unknown | 1 (0.1%) | 0 (0.0%) |
HER2 status** | ||
Positive | 279 (18.7%) | 49 (12.2%) |
Negative | 1,185 (79.4%) | 344(85.6%) |
Missing | 28 (1.9%) | 9 (2.2%) |
pN status | ||
pN0 | 836 (56.0%) | 319 (79.4%) |
pN1 (1–3) | 477 (32.0%) | 74 (18.4%) |
pN2 (4–9) | 113 (7.6%) | 6 (1.5%) |
pN3 (≥ 10) | 66 (4.4%) | 3 (0.7%) |